Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645197 | 0.82 | RAF1 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL318825 | 0.81 | RAF1 (0.32) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2218672 | 0.80 | ALDH1A1 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL669880 | 0.80 | RAF1 (0.36) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL101454 | 0.80 | RAF1 (0.39) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10206102 | 0.79 | SMN1; SMN2 (0.39) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15130865 | 0.79 | TBK1 (0.32) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL15130923 | 0.79 | TBK1 (0.32) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL670166 | 0.78 | NR1I2 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL670167 | 0.78 | NR1I2 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523951-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524764-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2523951-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011088303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES , INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES , INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
| US-20110178058-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | RAF1 1470/4885MAPK14 2109/4885MAPK13 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.